In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer pays $15.4bn in cash, $1.75bn in debt for Hospira

Executive Summary

Pfizer Inc. bought generics firm Hospira Inc. for $15.4bn in cash--$90 per share (a 39% premium)--plus $1.75bn in debt, and will finance the deal through a combination of cash (two-thirds) and debt (one-third).

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Infusion Therapy Equipment and Supplies
    • Monitoring Equipment & Devices
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash for Equity

Related Companies